Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 6 (2009), Issue 9 (September)

1. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
   Neurology, 73(9): 696-701. [Abstract] [Full-text]
2. Texture analysis of magnetization transfer maps from patients with clinically isolated syndrome and multiple sclerosis.
   J Magn Reson Imaging, 30(3): 506-13. [Abstract] [Full-text]
3. Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN.
   Eur J Immunol, 39(9): 2358-60. [Abstract] [Full-text]
4. Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T Cells in MS.
   Eur J Immunol, 39(9): 2525-36. [Abstract] [Full-text]
5. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.
   J Immunol, 183(6): 4067-76. [Abstract] [Full-text]
6. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis.
   J Neuropathol Exp Neurol, 68(9): 1021-8. [Abstract] [Full-text]
7. Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis.
   J Neuropathol Exp Neurol, 68(9): 1037-48. [Abstract] [Full-text]
8. Physical and cognitive functioning after 3 years can be predicted using information from the diagnostic process in recently diagnosed multiple sclerosis.
   Arch Phys Med Rehabil, 90(9): 1478-88. [Abstract] [Full-text]
9. Using fast eye movements to study fatigue in multiple sclerosis.
   Neurology, 73(10): 798-804. [Abstract] [Full-text]
10. Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis.
    Clin Exp Immunol, 158(1): 26-30. [Abstract] [Full-text]
11. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    N Engl J Med, 361(11): 1081-7. [Abstract] [Full-text]
12. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    N Engl J Med, 361(11): 1075-80. [Abstract] [Full-text]
13. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    N Engl J Med, 361(11): 1067-74. [Abstract] [Full-text]
14. Devic's syndrome as initial presentation of systemic lupus erythematosus.
    Am J Med Sci, 338(3): 245-7. [Abstract] [Full-text]
15. Protocol for the saMS trial (supportive adjustment for multiple sclerosis): a randomized controlled trial comparing cognitive behavioral therapy to supportive listening for adjustment to multiple sclerosis.
    BMC Neurol, 9: 45. [Abstract] [Full-text]
16. Spinal cord neuronal pathology in multiple sclerosis.
    Brain Pathol, 19(4): 642-9. [Abstract] [Full-text]
17. PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
    J Biol Chem, 284(38): 26070-84. [Abstract] [Full-text]
18. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
    Arch Neurol, 66(9): 1164-7. [Abstract] [Full-text]
19. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus.
    Arch Neurol, 66(9): 1160-3. [Abstract] [Full-text]
20. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis.
    Arch Neurol, 66(9): 1144-50. [Abstract] [Full-text]
21. Multiple sclerosis with predominant, severe cognitive impairment.
    Arch Neurol, 66(9): 1139-43. [Abstract] [Full-text]
22. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays.
    Arch Neurol, 66(9): 1134-8. [Abstract] [Full-text]
23. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients.
    Arch Neurol, 66(9): 1128-33. [Abstract] [Full-text]
24. Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.
    Clin Immunol, 133(1): 27-44. [Abstract] [Full-text]
25. Pathogenic CD8(+) T cells in multiple sclerosis.
    Ann Neurol, 66(2): 132-41. [Abstract] [Full-text]
26. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
    Ann Neurol, 66(2): 171-83. [Abstract] [Full-text]
27. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis.
    J Neuroimmunol, 214(1): 67-77. [Abstract] [Full-text]
28. A population-based case-control study on viral infections and vaccinations and subsequent multiple sclerosis risk.
    Eur J Epidemiol, 24(9): 541-52. [Abstract] [Full-text]
29. Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease.
    J Neuroimmunol, 214(1): 128-31. [Abstract] [Full-text]
30. Association of MMP1, MMP3, MMP9, and MMP12 polymorphisms with risk and clinical course of multiple sclerosis in a Polish population.
    J Neuroimmunol, 214(1): 113-7. [Abstract] [Full-text]
31. Does the DRB1*1501 allele confer more severe and faster progression in primary progressive multiple sclerosis patients? HLA in primary progressive multiple sclerosis.
    J Neuroimmunol, 214(1): 101-3. [Abstract] [Full-text]
32. Association study on two vitamin D receptor gene polymorphisms and vitamin D metabolites in multiple sclerosis.
    Ann N Y Acad Sci, 1173: 515-20. [Abstract] [Full-text]
33. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica.
    Ann N Y Acad Sci, 1173: 478-86. [Abstract] [Full-text]
34. Toll-like receptors in multiple sclerosis mouse experimental models.
    Ann N Y Acad Sci, 1173: 458-62. [Abstract] [Full-text]
35. Gluten sensitivity in multiple sclerosis: experimental myth or clinical truth?
    Ann N Y Acad Sci, 1173: 343-9. [Abstract] [Full-text]
36. Relapsing neuromyelitis optica: long term history and clinical predictors of death.
    J Neurol Neurosurg Psychiatry, 80(10): 1162-4. [Abstract] [Full-text]
37. Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria.
    J Neurol Neurosurg Psychiatry, 80(10): 1107-9. [Abstract] [Full-text]
38. Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis.
    J Neurol Neurosurg Psychiatry, 80(10): 1110-5. [Abstract] [Full-text]
39. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
    Neurol India, 57(4): 418-23. [Abstract] [Full-text]
40. Antibody-negative neuromyelitis optica with heavy B-cell infiltration.
    APMIS, 117(10): 768-72. [Abstract] [Full-text]
41. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha).
    Lab Invest, 89(10): 1076-83. [Abstract] [Full-text]
42. Prefrontal function associated with impaired emotion recognition in patients with multiple sclerosis.
    Behav Brain Res, 205(1): 280-5. [Abstract] [Full-text]
43. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.
    Neurology, 73(13): 1018-25. [Abstract] [Full-text]
44. Transcranial brain sonography findings predict disease progression in multiple sclerosis.
    Neurology, 73(13): 1010-7. [Abstract] [Full-text]
45. Primary progressive multiple sclerosis: tactile-associated functional MR activity in the cervical spinal cord.
    Radiology, 253(1): 209-15. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.